Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes.

Di Folco U, Vallecorsa N, Nardone MR, Pantano AL, Tubili C

Acta diabetologica17 Jul 2022Cited by 17 (Europe PMC)

PMID35842847PMCIDPMC9288662DOI10.1007/s00592-022-01936-6PepBankPUB-35842847

Summary

AimsAim of the present study was to evaluate the impact of once-weekly semaglutide on different end-points indicative of metabolic control, cardiovascular risk, dietary behavior, and treatment satisfaction in T2DM.MethodsThis was a retrospective observational study conducted in a diabetes clinic. Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed. Furthermore, at T1 patients were asked to fill-in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Control of Eating Questionnaire (COEQ).ResultsOverall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years). After 32 weeks of treatment with semaglutide, HbA1c levels were reduced by 1.38%, FBG by - 56.53 mg/dl, weight by 6.03 kg. Systolic and diastolic blood pressure, total, HDL-, LDL-, and non -HDL cholesterol, and triglycerides significantly improved. The number of glucose-lowering and antihypertensive drugs also decreased. At T1, DTSQ score was 32.23 ± 1.44, whereas COEQ indicated low levels of hunger and good control of eating.ConclusionsThe study documented benefits of semaglutide on metabolic control and multiple CV risk factors, simplification of therapeutic schemes and high satisfaction with diabetes treatment, and eating behaviors indicative of healthy diet and reduced food intake.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, HbA1c fell by 1.38% after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, long-term blood sugar fell after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n = 104
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Measurements
HbA1c change
−1.38%
32 weeks
Source sentences
Summary
After 32 weeks of treatment with semaglutide, HbA1c levels were reduced by 1.38%
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284701
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, fasting blood glucose fell by 56.53 mg/dl after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, fasting blood sugar fell after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseFasting blood glucose change
Study
n = 104
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Measurements
Fasting blood glucose change
−56.53 mg/dl
32 weeks
Source sentences
Summary
After 32 weeks of treatment with semaglutide, HbA1c levels were reduced by 1.38%, FBG by - 56.53 mg/dl
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284702
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, body weight fell by 6.03 kg after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, body weight fell after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n = 104
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Measurements
Body weight change
−6.03 kg
32 weeks
Source sentences
Summary
After 32 weeks of treatment with semaglutide, HbA1c levels were reduced by 1.38%, FBG by - 56.53 mg/dl, weight by 6.03 kg.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284703
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, systolic blood pressure improved significantly after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, systolic blood pressure improved after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure
Study
n = 104
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Source sentences
Summary
Systolic and diastolic blood pressure, total, HDL-, LDL-, and non -HDL cholesterol, and triglycerides significantly improved.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284704
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, diastolic blood pressure improved significantly after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, diastolic blood pressure improved after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseDiastolic blood pressure
Study
n = 104
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Source sentences
Summary
Systolic and diastolic blood pressure, total, HDL-, LDL-, and non -HDL cholesterol, and triglycerides significantly improved.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284705
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, total cholesterol improved significantly after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, total cholesterol improved after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseTotal cholesterol
Study
n = 104
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Source sentences
Summary
Systolic and diastolic blood pressure, total, HDL-, LDL-, and non -HDL cholesterol, and triglycerides significantly improved.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284706
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, HDL cholesterol improved significantly after 32 weeks of semaglutide; the direction of change was not stated.
In plain wordsIn adults with type 2 diabetes, HDL cholesterol improved after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedHDL cholesterol
Study
n = 104
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Source sentences
Summary
Systolic and diastolic blood pressure, total, HDL-, LDL-, and non -HDL cholesterol, and triglycerides significantly improved.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284707
08HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, LDL cholesterol improved significantly after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, LDL cholesterol improved after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseLDL cholesterol
Study
n = 104
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Source sentences
Summary
Systolic and diastolic blood pressure, total, HDL-, LDL-, and non -HDL cholesterol, and triglycerides significantly improved.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284708
09HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, non-HDL cholesterol improved significantly after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, non-HDL cholesterol improved after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseNon-HDL cholesterol
Study
n = 104
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Source sentences
Summary
Systolic and diastolic blood pressure, total, HDL-, LDL-, and non -HDL cholesterol, and triglycerides significantly improved.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284709
10HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, triglycerides improved significantly after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, triglycerides improved after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseTriglycerides
Study
n = 104
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Source sentences
Summary
Systolic and diastolic blood pressure, total, HDL-, LDL-, and non -HDL cholesterol, and triglycerides significantly improved.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284710
11HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, the number of glucose-lowering drugs decreased after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, patients used fewer other diabetes drugs after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseNumber of glucose-lowering drugs
Study
n = 104
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Source sentences
Summary
The number of glucose-lowering and antihypertensive drugs also decreased.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284711
12HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, the number of antihypertensive drugs decreased after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, patients used fewer blood pressure drugs after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseNumber of antihypertensive drugs
Study
n = 104
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Source sentences
Summary
The number of glucose-lowering and antihypertensive drugs also decreased.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284712
13HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, the Diabetes Treatment Satisfaction Questionnaire score was 32.23 after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, treatment satisfaction was scored after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
Not applicableDiabetes Treatment Satisfaction Questionnaire score
Study
n = 104
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Measurements
DTSQ score
32.23 points
32 weeks
Source sentences
Summary
At T1, DTSQ score was 32.23 ± 1.44, whereas COEQ indicated low levels of hunger and good control of eating.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284713
14HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, the Control of Eating Questionnaire indicated low hunger and good control of eating after 32 weeks of semaglutide.
In plain wordsIn adults with type 2 diabetes, questionnaire answers showed low hunger and good control of eating after 32 weeks of semaglutide.
Peptide
Semaglutide
Outcome
Not applicableHunger and control of eating (COEQ)
Study
n = 104
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · 32 weeksAs given in this study (human).
Source sentences
Summary
whereas COEQ indicated low levels of hunger and good control of eating.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective observational study conducted in a diabetes clinic.
Summary · context
Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed.
Summary · context
Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years).
Show in the study text Report a problemFND-3584284714

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes.

Summary

Results from this study14

Version history

Subjects

Publication types

MeSH terms

Keywords